Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Over And Out For Solanezumab, While Biogen Takes The Spotlight
Over And Out For Solanezumab, While Biogen Takes The Spotlight
Over And Out For Solanezumab, While Biogen Takes The Spotlight
Submitted by
admin
on December 13, 2016 - 10:22am
Source:
Seeking Alpha
News Tags:
solanezumab
Biogen
Eli Lilly
aducanumab
Alzheimer's disease
Headline:
Over And Out For Solanezumab, While Biogen Takes The Spotlight
Do Not Allow Advertisers to Use My Personal information
